Equities

Deciphera Pharmaceuticals Inc

Deciphera Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)15.73
  • Today's Change0.55 / 3.62%
  • Shares traded883.14k
  • 1 Year change+4.80%
  • Beta0.3788
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.

  • Revenue in USD (TTM)163.36m
  • Net income in USD-194.94m
  • Incorporated2017
  • Employees355.00
  • Location
    Deciphera Pharmaceuticals Inc200 Smith StWALTHAM 02451-0099United StatesUSA
  • Phone+1 (781) 209-6400
  • Fax+1 (302) 655-5049
  • Websitehttps://www.deciphera.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SAGE Therapeutics Inc86.46m-541.49m1.14bn487.00--1.43--13.24-9.05-9.051.4413.320.0772--1.79177,527.70-48.37-21.88-52.66-23.3097.5099.63-626.32-131.50----0.00--1,024.84-0.8606-1.63---28.01--
Liquidia Corp17.49m-78.50m1.15bn136.00--21.87--65.52-1.21-1.210.26910.68910.1413--3.85128,588.20-63.43-55.02-71.31-62.6983.4982.18-448.89-474.59---26.140.4942--9.7545.23-91.40--66.93--
Mirum Pharmaceuticals Inc186.37m-163.42m1.18bn264.00--4.72--6.34-4.08-4.084.565.320.37293.374.05705,962.10-32.70-38.93-38.55-44.8874.76---87.68-190.714.19-79.670.552--141.85---20.45--21.81--
Belite Bio Inc (ADR)0.00-31.63m1.19bn20.00--12.87-----1.24-1.240.003.100.00----0.00-45.54---47.50--------------0.00-------150.09------
Scholar Rock Holding Corp0.00-165.79m1.20bn150.00--5.21-----1.99-1.990.002.960.00----0.00-49.55-38.14-55.26-44.31-------647.95----0.1817---100.00---23.26---45.61--
Pharvaris NV0.00-116.19m1.22bn65.00--5.81-----3.18-3.180.004.040.00----0.00-57.65---63.41-------------6.960.0019-------78.64------
Deciphera Pharmaceuticals Inc163.36m-194.94m1.23bn355.00--3.48--7.51-2.29-2.291.924.360.35220.17876.01460,157.80-42.03-44.54-52.63-52.2497.72---119.34-245.883.59--0.00--21.87---8.95---7.11--
MannKind Corp198.96m-11.94m1.25bn414.00------6.29-0.0464-0.04640.7087-0.91160.51652.5012.55480,584.50-3.10-26.07-3.99-37.8068.4559.68-6.00-57.613.310.50231.90--99.4248.1786.34--160.47--
Ligand Pharmaceuticals Inc131.31m53.82m1.26bn58.0024.521.7913.979.612.912.817.2639.920.16950.56424.152,264,035.006.9412.327.5012.9991.9981.6540.9880.3212.72--0.00001---33.09-12.181,131.21-17.8642.63--
Tarsus Pharmaceuticals Inc17.45m-135.89m1.30bn244.00--6.00--74.29-4.58-4.580.59395.760.0707--1.6471,504.10-55.09-31.56-61.63-33.8290.87---778.89-242.596.85--0.1315---32.42---118.86--279.39--
Collegium Pharmaceutical Inc566.77m48.16m1.31bn197.0046.376.676.622.310.88230.882312.536.130.48916.103.132,876,990.004.162.796.754.8057.5550.888.505.161.102.590.77340.0022.1715.11292.60---54.77--
AbCellera Biologics Inc38.03m-146.40m1.31bn586.00--1.13--34.57-0.5062-0.50620.13153.960.0251--1.1064,890.79-9.676.08-10.496.67-----384.9924.697.32--0.000.00-92.1733.91-192.35--70.96--
Gyre Therapeutics Inc0.00-44.24m1.34bn7.00---------20.60-20.600.001.390.00----0.00-215.90-58.25-235.61-72.12-------817.06----0.00---89.18-4.8590.63------
Ironwood Pharmaceuticals, Inc.442.74m-1.00bn1.35bn267.00------3.05-6.51-6.512.59-2.210.5634--3.621,658,184.00-131.28-4.54-162.45-5.20-----233.00-7.81--63.791.98--7.835.02-672.50--160.10--
Data as of Mar 28 2024. Currency figures normalised to Deciphera Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

37.27%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 31 Dec 20235.20m6.44%
Redmile Group LLCas of 31 Dec 20234.80m5.94%
BlackRock Fund Advisorsas of 31 Dec 20234.79m5.92%
The Vanguard Group, Inc.as of 31 Dec 20234.31m5.33%
SSgA Funds Management, Inc.as of 31 Dec 20232.47m3.06%
Morgan Stanley & Co. LLCas of 31 Dec 20232.10m2.59%
Polar Capital LLPas of 31 Dec 20231.85m2.29%
Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 20231.82m2.25%
Dimensional Fund Advisors LPas of 31 Dec 20231.56m1.93%
Geode Capital Management LLCas of 31 Dec 20231.22m1.51%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.